The University of California, San Francisco cancer of the prostate risk assessment score: A straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy

被引:623
作者
Cooperberg, MR
Pasta, DJ
Elkin, EP
Litwin, MS
Latini, DM
DuChane, J
Carroll, PR
机构
[1] Univ Calif San Francisco, Mt Zion Canc Ctr, San Francisco, CA 94115 USA
[2] Univ Calif Los Angeles, Los Angeles, CA USA
[3] TAP Pharmaceut Prod Inc, Lake Forest, IL USA
关键词
prostatic neoplasms; risk factors; prognosis; prostate-specific antigen;
D O I
10.1097/01.ju.0000158155.33890.e7
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Multivariate prognostic instruments aim to predict risk of recurrence among patients with localized prostate cancer. We devised a novel risk assessment tool which would be a strong predictor of outcome across various levels of risk, and which could be easily applied and intuitively understood. Materials and Methods: We studied 1,439 men diagnosed between 1992 and 2001 who had undergone radical prostatectomy and were followed in the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) database, a longitudinal, community based disease registry of patients with prostate cancer. Disease recurrence was defined as prostate specific antigen (PSA) 0.2 ng/ml or greater on 2 consecutive occasions following prostatectomy or a second cancer treatment more than 6 months after surgery. The University of California, San Francisco-Cancer of the Prostate Risk Assessment (UCSF-CAPRA) score was developed using preoperative PSA, Gleason score, clinical T stage, biopsy results and age. The index was developed and validated using Cox proportional hazards and life table analyses. Results: A total of 210 patients (15%) had recurrence, 145 by PSA criteria and 65 by second treatment. Based on the results of the Cox analysis, points were assigned based on PSA (0 to 4 points), Gleason score (0 to 3), T stage (0 to 1), age (0 to 1) and percent of biopsy positive cores (0 to 1). The UCSF-CAPRA score range is 0 to 10, with roughly double the risk of recurrence for each 2-point increase in score. Recurrence-free survival at 5 years ranged from 85% for a UCSF-CAPRA score of 0 to 1 (95% CI 73%-92%) to 8% for a score of 7 to 10 (95% Cl 0%-28%). The concordance index for the UCSF-CAPRA score was 0.66. Conclusions: The UCSF-CAPRA score is a straightforward yet powerful preoperative risk assessment tool. It must be externally validated in future studies.
引用
收藏
页码:1938 / 1942
页数:5
相关论文
共 20 条
[11]   Cancer statistics, 2004 [J].
Jemal, A ;
Tiwari, RC ;
Murray, T ;
Ghafoor, A ;
Samuels, A ;
Ward, E ;
Feuer, EJ ;
Thun, MJ .
CA-A CANCER JOURNAL FOR CLINICIANS, 2004, 54 (01) :8-29
[12]   A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer [J].
Kattan, MW ;
Eastham, JA ;
Stapleton, AMF ;
Wheeler, TM ;
Scardino, PT .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (10) :766-771
[13]   Long-term cancer control of radical prostatectomy in men younger than 50 years of age: Update 2003 [J].
Khan, MA ;
Han, M ;
Partin, AW ;
Epstein, JI ;
Walsh, PC .
UROLOGY, 2003, 62 (01) :86-91
[14]   The CaPSURE database: A methodology for clinical practice and research in prostate cancer [J].
Lubeck, DP ;
Litwin, MS ;
Henning, JM ;
Stier, DM ;
Mazonson, P ;
Fisk, R ;
Carroll, PR .
UROLOGY, 1996, 48 (05) :773-777
[15]   Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: Data from CaPSURE [J].
Mitchell, JA ;
Cooperberg, MR ;
Elkin, EP ;
Lubeck, DP ;
Mehta, SS ;
Kane, CJ ;
Carroll, PR .
JOURNAL OF UROLOGY, 2005, 173 (04) :1126-1131
[16]   Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium [J].
Partin, AW ;
Mangold, LA ;
Lamm, DM ;
Walsh, PC ;
Epstein, JI ;
Pearson, JD .
UROLOGY, 2001, 58 (06) :843-848
[17]   Positive fraction of systematic biopsies predicts risk of relapse after radical prostatectomy [J].
Presti, JC ;
Shinohara, K ;
Bacchetti, P ;
Tigrani, V ;
Bhargava, V .
UROLOGY, 1998, 52 (06) :1079-1084
[18]  
Ross PL, 2001, J UROLOGY, V165, P1562, DOI 10.1016/S0022-5347(05)66349-5
[19]   Prostate cancer in men age 50 years or younger: A review of the Department of Defense Center for Prostate Disease Research multicenter prostate cancer database [J].
Smith, CV ;
Bauer, JJ ;
Connelly, RR ;
Seay, T ;
Kane, C ;
Foley, J ;
Thrasher, JB ;
Kusuda, L ;
Moul, JW .
JOURNAL OF UROLOGY, 2000, 164 (06) :1964-1967
[20]   Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer [J].
Wei, JT ;
Dunn, RL ;
Sandler, HM ;
McLaughlin, PW ;
Montie, JE ;
Litwin, MS ;
Nyquist, L ;
Sanda, MG .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (02) :557-566